Fusion Antibodies plc announced Tim Watts, Non-executive Director since December 2017, has informed the Board of his intention to retire and, therefore, will not be seeking re-election at the AGM. He will cease to be a Director of the Company at the close of the AGM. Colin Walsh, Non-executive Director will take up the position of Chair of the Company's Audit Committee in place of Tim Watts.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.45 GBX | 0.00% | -9.21% | -18.82% |
May. 23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
May. 23 | Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.82% | 4.21M | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- FAB Stock
- News Fusion Antibodies plc
- Fusion Antibodies plc Announces Director Changes